NGL Fine-Chem Ltd
Company Profile
Business description
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
Contact
301, E Square, Subhash Road
Vile Parle (East)
MumbaiMH400057
INDT: +91 2240842222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2027
Employees
523
Stocks News & Analysis
stocks
Expanding store network for ASX listed retailer
stocks
SpaceX jumps 19% in debut, but hurdles lie ahead
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,134.50 | 21.10 | 0.23% |
| CAC 40 | 8,350.87 | 150.08 | 1.83% |
| DAX 40 | 24,635.30 | 425.59 | 1.76% |
| Dow JONES (US) | 51,202.26 | 353.51 | 0.70% |
| FTSE 100 | 10,471.72 | 167.84 | 1.63% |
| HKSE | 24,829.11 | 111.01 | 0.45% |
| NASDAQ | 25,888.84 | 79.18 | 0.31% |
| Nikkei 225 | 69,305.85 | 3,285.81 | 4.98% |
| NZX 50 Index | 13,372.49 | 21.38 | -0.16% |
| S&P 500 | 7,431.46 | 37.16 | 0.50% |
| S&P/ASX 200 | 8,922.80 | 15.80 | 0.18% |
| SSE Composite Index | 4,068.58 | 37.06 | 0.92% |